Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
October 12, 2022 20:10 ET | Source: DICE Therapeutics, Inc.

DICE Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
October 11, 2022 16:01 ET | Source: DICE Therapeutics, Inc.

DICE Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
October 11, 2022 07:00 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with...
August 11, 2022 16:10 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

Completed enrollment in Phase 1 clinical trial of lead oral IL-17 antagonist DC-806; topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN...
July 21, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE),...
June 01, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
May 12, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

Topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients expected in mid-2022Current cash provides runway through mid-2024...
May 03, 2022 08:00 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
March 28, 2022 16:05 ET | Source: DICE Therapeutics, Inc.

DICE Therapeutics Expands Management Team and Board of Directors

Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE...